training on revised sops: sop 8.3: delegation of authority ... · training on revised sops: sop...
TRANSCRIPT
![Page 1: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/1.jpg)
SOP Updates
Tatiana Kurilo, MPH, CCRC Quality Management and Education
![Page 2: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/2.jpg)
Outline • Training on revised SOPs: SOP 3.5: Reporting Unanticipated Problems/Adverse Events SOP 3.7: Preauthorization of Treatment Effective February 2, 2015! * Updated Winship Adverse Event worksheet *
![Page 3: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/3.jpg)
3.5 Reporting Unanticipated Problems/Adverse Events
• Purpose: To standardize the reporting of
significant events for clinical trials. • Scope: All Winship investigators and staff
involved in the management of subjects who participate in cancer-related clinical research trials.
![Page 4: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/4.jpg)
3.5 Reporting Unanticipated Problems/Adverse Events
Procedure:
• It is the Primary Investigator’s (PI)
responsibility to review and assess all adverse events (AE)
• The PI may delegate AE assessment (grading & attribution) to Licensed study staff that is listed on Form 1572 and assigned this task on DOA log unless specified otherwise in the protocol
![Page 5: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/5.jpg)
3.5 Reporting Unanticipated Problems/Adverse Events Procedure:
• The PI is responsible for understanding the
Sponsor’s reporting requirements • The regulatory specialist will submit
reportable events as required to the sponsor and the IRB
• Emory sponsors and sponsor-investigators (S-Is) must fulfill the additional FDA reporting requirements of sponsors
![Page 6: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/6.jpg)
3.5 Reporting Unanticipated Problems/Adverse Events Procedure:
• For SAEs and Ups, the Investigator, with the
assistance of the CRC/CRN, will complete and sign the Emory University Reportable Event Assessment Form
• The regulatory specialist will review the Emory assessment form to determine IRB reporting requirements
![Page 7: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/7.jpg)
![Page 8: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/8.jpg)
3.5 Reporting Unanticipated Problems/Adverse Events Procedure:
• The CRC/CRN will complete the following:
– Enter all events on Winship Adverse Event worksheet in the subject’s study records (available on Intranet)
– Enter all SAE(s) and UP(s) into Oncore® within the SAE category, in timely matter
– Maintain documentation of event(s) assessment and submission in the subject’s study records
– Ensure inclusion of all UP(s) and SAE(s) on the agenda for discussion at the regularly scheduled Working Group meetings
![Page 9: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/9.jpg)
![Page 10: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/10.jpg)
3.7 Preauthorization of Treatment
• Purpose: To ensure that health insurance preauthorization is completed for subjects receiving commercially supplied medications in clinical trials.
• Scope: All Winship investigators and staff involved in the management of subjects who participate in cancer-related clinical research trials.
![Page 11: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/11.jpg)
3.7 Preauthorization of Treatment
Procedure:
• This procedure refers to orders for all studies
with commercially supplied medication that require health insurance preauthorization including IV or injection chemotherapy or any IV or injection medication, therapy or regimen..
![Page 12: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/12.jpg)
3.7 Preauthorization of Treatment
Procedure:
When a subject has signed consent to participate in a clinical trial and trial eligibility is confirmed, the CRC or CRN will complete an order form for that clinical trial with the following information: 1. Anticipated start date 2. Estimated doses of therapeutic agents supplied
based on subject's current height and weight The words “FOR PRECERT ONLY” will be written on the physician signature line.
![Page 13: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/13.jpg)
3.7 Preauthorization of Treatment
Procedure:
• The CRC/CRN will Fax Precert Only orders directly to AIC Scheduler office at 404-778-5819 at least Five business days prior to the planned treatment date
EHC observed holidays are not counted as business days and orders received after 4PM will be considered the following business day.
![Page 14: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/14.jpg)
Questions..
![Page 15: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/15.jpg)
Multi-Site SOP 10.6 Reporting Unanticipated
Problems/Adverse Events
Effective January 30, 2015!
Nikki Brumbelow, MS, CCRC
![Page 16: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/16.jpg)
10.6 Reporting Unanticipated Problems/Adverse Events PI & SI
• PI: Review and assess all AEs & ensure reported to Emory
within protocol specified timelines: SAE & UPs= 24 hours of awareness
• SI: Review and sign off* on every event & return to Winship regulatory staff to report to IRB/FDA, as applicable
* Emory Reportable Event Assessment Form will be used for Participating Sites to complete and SI to review and sign off
![Page 17: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/17.jpg)
10.6 Reporting Unanticipated Problems/Adverse Events Participating Site Responsibilities:
• Complete applicable reporting form per protocol & submit to Winship regulatory
• Report event to their IRB as applicable • Submit acknowledgments from their IRB to Winship
regulatory • Resolve all event related queries in a timely manner • Maintain copies of each event in subject's chart • Enter AEs on an AE worksheet in subject chart • Enter AEs in Oncore®in a timely manner • Enter SAEs and UPs into Oncore® in the SAE Category
in a timely manner
![Page 18: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/18.jpg)
10.6 Reporting Unanticipated Problems/Adverse Events Winship Regulatory Responsibilities:
• Follow IRB policies and procedures • Follow FDA reporting requirements • Ensure SI signs off on all events prior to
submitting
![Page 19: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/19.jpg)
QUESTIONS?
![Page 20: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/20.jpg)
Mastering Clinical Research
For previous presentations and upcoming schedule, visit:
• https://winshipcancer.emory.edu/education/continuing-education/mastering-clinical-research.html
![Page 21: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/21.jpg)
Post Questions
![Page 22: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/22.jpg)
Question 1: The Principal Investigator provides oversight of all adverse events.
A. True B. False
![Page 23: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/23.jpg)
Question 2: The Principal Investigator may delegate attribution of Adverse
Events to:
A. Lead Working Group Coordinator B. Clinical Research Coordinator who
is assigned to the study C. Clinical Research Nurse that is
listed on Form 1572 ans assigned this task on DOA
![Page 24: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/24.jpg)
Question 3: For commercially supplied study drugs the “Precert Only” order
must be Faxed directly to AIC Scheduler:
A. At least one business day prior to patient’s treatment
B. At least Five business days prior to patient’s treatment date
C. After patient receives his/her first study treatment
![Page 25: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/25.jpg)
Question 4: Multi-Site: The Sponsor-Investigator must sign off on every Reportable Event Assessment Form
filled out by participating sites?
A. True B. False
![Page 26: Training on revised SOPs: SOP 8.3: Delegation Of Authority ... · Training on revised SOPs: SOP 8.3: Delegation Of Authority SOP 5.2: Opening a Clinical Trial to Accrual Refresher](https://reader036.vdocuments.us/reader036/viewer/2022081617/60852ce880946c7c3375d516/html5/thumbnails/26.jpg)
Question 5: Multi-Site: Which of the following is a task for which the Winship
team is responsible?
A. Resolve all event related queries B. Enter AEs on an and AE worksheet in
subject chart C. Ensure SI signs off on all events prior
to submitting the events to IRB/FDA D. Enter SAEs and Ups in OnCore